ClinicalTrials.gg
Active, not recruitingNCT05668780BIRCHUpdated Sep 14, 2026

Buprenorphine Integration Research and Community Health

An interventional study of NIATx Coaching in Opioid Use Disorder, HIV Infections and Hepatitis C, sponsored by Yale University. Active, not recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by Yale University · Not applicable, Interventional, and Health services research

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies in Opioid-Related Disorders by Yale University — 20 open to participants now, 24 under way, 1 of them phase 3. Opioid-Related Disorders · Yale University.

Enrollment
67th of 94
20 · median 62
Started
2023
with 7 others
No phase
44 of 106
7 open now
Primary completion
2027-05
later than 9 of 23 live
Registered
83rd of 106
by date

Among the 106 studies in Opioid-Related Disorders by Yale University, this one is the 67th largest by enrollment of the 94 interventional ones that give a count, is one of 8 that started in 2023, is one of 44 with no phase, reaches primary completion later than 9 of the 23 other live ones, and was the 83rd registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

20 of the 106 studies in Opioid-Related Disorders by Yale University are open now, in 4 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Opioid-Related Disorders by Yale University, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate an intervention strategy in introducing screen/evaluate/treat (SET) procedures for HIV/ hepatitis C/ and Opioid Use Disorder in Primary Care Clinics in West Virginia.

The main questions it aims to answer are:

  • What are the barriers and facilitators to integrating evidence based practices for screening and treatment of HIV, hepatitis C, and Opioid Use Disorder into primary care clinics in West Virginia?
  • To assess the extent to which our SET processes are achieved through enhanced EHR tools, NIATx (formerly known as Network for the Improvement of Addiction Treatment) facilitation and Extension for Community Healthcare Outcomes (ECHO)-supported collaborative learning?
  • Does implementing these services improve primary and secondary health outcomes for patients? Primary Care Clinics will participate in training and process improvement coaching to integrate these services. Using a step-wise design, 20 Primary Care Clinics will undergo the training and coaching in four groups of five clinics.
Read the detailed description

To integrate HIV/HCV/ OUD services into Primary Care Clinics (PCC), the investigators will introduce screen/evaluate/treat (SET) procedures for HIV/hepatitis C (HCV)/ Opioid Use Disorder (OUD) in PCCs in rural WV where ECHO and WV Hepatitis Academic Mentoring Partnership (WVHAMP) will support clinical skills for Primary Care Provider (PCPs) and where NIATx process improvement tools will be used to guide adoption and scale-up of SET procedures to achieve integration. Using a step-wedge design with 20 PCCs, the investigators will conduct a Type 3 Hybrid implementation trial and examine the extent to which our SET processes are achieved through enhanced electronic health record (EHR) tools, NIATx facilitation and ECHO and WVHAMP collaborative learning. Implementation outcomes include adoption of screening and treating with three distinct but linked evidence based practices (EBPs) for OUD, HIV and HCV in PCCs. Effectiveness outcomes will include quality health indicators (QHIs) for primary care, HIV, HCV and OUD.

This project is separated into two Phases. Phase 1 includes Nominal Group Technique focus groups and anonymous staff surveys at the 20 PCCs to identify barriers and facilitators to integrating these evidence based practices. Phase 2 is an evaluation of deidentified reports from the PCCs Electronic Health Records. In Phase 2, randomized sites will start NIATx activities, including a series of rapid-cycle Plan-Do-Study-Act (PDSA) activities. The first 6 months will include intensive coaching from a certified NIATx coach and enhanced by support from ECHO \& the WVHAMP to teach subspecialty clinical expertise. During an 18-month follow-up, the investigators will assess the sustainability of these practice changes. Effectiveness outcomes will include a set of nationally recommended quality health indicators (QHIs) to measure quality care. This project is a collaboration between Yale University, West Virginia University (WVU), and the West Virginia Primary Care Association.

Aim 1 (Phase 1):

Identify the barriers and facilitators for a diverse group of PCCs throughout WV, a mostly rural state that is profoundly impacted by OUD-associated HIV/HCV outbreaks, focusing on screening for and prescribing evidence-based treatment [medication for opioid use disorder (MOUD), Treatment as Prevention (TasP), pre-exposure prophylaxis (PrEP), and curative hepatitis C (HCV) treatment] for OUD, HIV and HCV.

Aim 2 (Phase 2):

Using a step-wedge design with 20 PCCs, the investigators will conduct a Type 3 hybrid implementation trial using the Integrated Promoting Action on Research Implementation in Health Services (iPARiHS) framework to assess the extent to which our SET processes are achieved through enhanced EHR tools, NIATx facilitation and ECHO-supported collaborative learning. Implementation outcomes include adoption of screening and implementation of three distinct but linked EBPs for OUD, HIV and HCV in PCCs. Effectiveness outcomes will include quality health indicators (QHIs) for primary care, HIV, HCV and OUD.

03

Conditions studied

  • Opioid Use Disorder
  • HIV Infections
  • Hepatitis C

Keywords

  • Implementation Science
  • HIV
  • Medication for Opioid Use Disorder
  • PrEP
  • Hepatitis C
  • Nominal Group Technique
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Federally Qualified Health Centers (FQHCs) and Look-Alike FQHC Primary Care Clinics in West Virginia providing adult care

Exclusion criteria

Exclusion Criteria:

  • Clinics (private or specialty) or any clinics not in West Virginia
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Intervention - Nominal Group Technique, Training, Coaching

    Each group of clinics will receive the same intervention in a step-wedge design, starting every 6-months.

    Behavioral: NIATx Coaching

Interventions

  • BehavioralNIATx Coaching

    The intervention will consist of: 1. a Nominal Group Technique session to identify priorities in integrating HIV/HCV/MOUD 2. rapid cycle improvement coaching sessions from a NIATx coach, using data dashboards and screening alerts to improve identification and treatment for HIV/HCV/OUD 3. training for primary care providers

06

What researchers measure

Primary outcomes

  1. Organizational Readiness and Staff Attitudes towards integration of OUD, HIV, HCV services into primary care clinics

    Staff survey results on organizational capacity, readiness to change, organizational functioning and social dominance orientation, and resistance to change.

    Time frame: Every 6 months for 24 months

  2. Integration of services

    Adoption of screening and implementation of best evidence-based practices. Quality health indicators (QHIs) for primary care - OUD, HIV \& HCV documented in electronic health record data.

    Time frame: 24 months

  3. Number of patients screened for opioid use disorder (OUD)

    Screening result for opioid use disorder documented in electronic health record (EHR)

    Time frame: 18 months

  4. Number of patients initiated on medications for OUD

    Prescription medication for OUD; prescription dates, medication type

    Time frame: 18 months

  5. Number of patients screened for HIV

    Lab ordered and result for HIV test entered in EHR

    Time frame: 18 months

  6. Number of patients initiated on antiretroviral medication (ART) for HIV

    For those with a positive HIV test result, prescription medication for HIV; prescription dates

    Time frame: 18 months

  7. Number of patients screened for Hepatitis C (HCV)

    Lab result ordered for HCV antibody / reflex polymerase chain reaction (PCR), result entered in EHR

    Time frame: 18 months

  8. Number of patients initiated on medication for HCV

    For those with a positive HCV PCR test, documented in EHR prescription medication for HCV; prescription dates; fibrosis score

    Time frame: 18 months

  9. Number of patients prescribed PrEP

    For those with a negative HIV result, prescription medication for PrEP; medication type; prescription dates; lab orders

    Time frame: 18 months

Secondary outcomes

  1. Number of patients with sustained viral response for HCV

    For those with HCV medication prescription; Viral load results in EHR after recommended treatment

    Time frame: 18 months

  2. Number of patients retained on medication for OUD for at least 6 months

    For those with prescription for medication for OUD; documentation in EHR of repeated prescription orders

    Time frame: 6 months

  3. Number of patients retained on medication (ART) for HIV

    For those with new prescription for medication for HIV; documentation in EHR of repeated prescriptions up to 6 and 12 months

    Time frame: 12 months

  4. Number of patients with Viral Suppression for HIV

    For those with new HIV diagnosis; documentation in EHR of viral suppression defined as HIV RNA \<200 copies/µl, at 6 and 12 months after prescription

    Time frame: 12 months

  5. Number of patients on PrEP to prevent HIV

    Documentation of negative HIV labs in EHR every 3 months

    Time frame: 12 months

  6. Quality Health Indicator (QHI) score for Primary Care screening variables

    QHI-PC score based on documentation of screening (limited age/sex) for hypertension, diabetes, hyperlipidemia, HIV, HCV, hepatitis B (HBV), syphilis, cervical cancer, breast cancers, prostate cancer, herpes simplex virus (HSV) serology, latent tuberculosis (TB), colorectal cancer, depression, chlamydia, gonorrhea.

    Time frame: 18 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for May 2027, 52 months after the start.

Of 465 non-industry interventional studies with no phase under Opioid-Related Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 47. This study's planned 52 months is above that.

Counting every sponsor, half of 496 studies reached it within 29 months; a quarter within 13 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2022
First posted
Dec 30, 2022
StartActual
Jan 24, 2023
Primary completionEst.
May 31, 2027
CompletionEst.
May 31, 2027
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05668780
Lead sponsor
Yale University
Responsible party
Sponsor
First posted
Dec 30, 2022
Start date
Jan 24, 2023
Primary completion
May 31, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Sep 14, 2026

Study contacts

Frederick L Altice, MD
principal investigator · Yale University
Natalie Kil, MPH
study director · Yale University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion